We will see....but if it performs well, man, it's another proof of the concept. For example, check a company called InSilico and you will see how many big pharma companies are using their AI/ML services to develop their own solutions...
Anyway...a clinical trial is soon to begin evaluating Pocenbrodib hydrochloride, a new investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). Developed using advanced artificial intelligence, Pocenbrodib targets mechanisms not addressed by current therapies.
Finally Undetectable PSA on BAT
FDA Grants Priority Review to Olaparib for HRR-Mutant mCRPC - Targeted Oncology - January 20, 2020